Updated · American Council on Science and Health · Jun 24
Researchers Identify 1,100-Dalton Manikomycin Targeting New Ribosome E-Site
Updated
Updated · American Council on Science and Health · Jun 24
Researchers Identify 1,100-Dalton Manikomycin Targeting New Ribosome E-Site
3 articles · Updated · American Council on Science and Health · Jun 24
Summary
Manikomycin binds a previously untargeted bacterial ribosome E-site, giving antibiotic researchers a new mechanism against resistant pathogens including some Gram-negative bacteria.
MICs of about 32 μg/mL against E. coli and 16 μg/mL against Klebsiella pneumoniae suggest only modest potency, making effective exposure in patients harder to achieve.
The molecule’s size—more than 1,100 daltons with multiple positive charges—also raises manufacturing, formulation and tissue-penetration concerns common in antibiotic development.
Mouse data added to those doubts: manikomycin cleared with a roughly 36-minute half-life, produced modest peak blood levels and failed in initial infection studies because exposure appeared too low.
Even if the compound itself falls short, the work establishes the bacterial E-site as a druggable target that could guide smaller, more potent follow-on antibiotics.
We've found a new way to kill superbugs. Why can't we turn this discovery into a life-saving pill?
If nature’s antibiotic is too weak for medicine, can chemists build a better one from its blueprint?
Manikomycin’s Breakthrough: Overcoming Pharmacokinetic Hurdles to Deliver a New Class of Antibiotics Against AMR
Overview
Manikomycin is a promising new antibiotic candidate urgently needed to fight rising drug resistance, but its development faces major challenges. As a giant molecule weighing over 1,100 daltons with multiple positive charges, it is difficult to manufacture and formulate. These unique features make it hard to turn Manikomycin from a laboratory discovery into a usable medicine. Its complex structure not only complicates production but also affects how the drug moves and works in the body, highlighting the need for further optimization before it can become an effective treatment.